ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026
Impact of vector copy number on critical quality attributes of retrovirally engineered T cells.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Single-cell vector copy number analysis of phenotypically defined long-term hematopoietic stem cells for gene therapy safety assessment.Molecular therapy. Advances · 2026Article
- Discovery of a novel envelope protein derived from simian retrovirus 2 for pseudotyping retroviral vectors used for production of CAR immune cells.Nature communications · 2026Article
- Targeting solid tumors with TCR-T cells: mechanisms, progress, and challenges.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Genetically engineered T cell therapies are approved by the FDA for the treatment of various cancers. The cell products in these treatments are manufactured using retroviral vectors to insert an antigen-targeting receptor into the T cell genome. Limited data exist on how vector copy number (VCN) per transduced cell impacts critical quality attributes (CQAs) of retrovirally engineered T cell products. We investigated the effect of VCN on the purity and potency of E7 T cells, a T cell receptor (TCR)-engineered cell product that has shown safety and clinical activity in human papillomavirus (HPV)-associated cancers. An increased VCN correlated with enhanced functional characteristics, including transduction efficiency, tumor recognition as measured by IFN-γ production, and cytotoxic activity in real-time killing assays. We then analyzed archived retention vials from E7 T cell products from a clinical trial prior to FDA guidance on VCN limits. The median VCN was >5, and there were no cases of insertional oncogenesis. These findings demonstrate a positive correlation between VCN and improved cell product purity and potency and contribute to existing clinical data showing a low risk of insertional oncogenesis in retrovirally engineered T cell therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.